DMT for depression: scientists test if the psychedelic experience matters

NCT ID NCT06927076

Recruiting now Symptom relief Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to find out whether DMT, a psychedelic drug, helps with depression because of the 'trip' itself or because of biological changes in the brain. 112 adults with major depression will receive DMT or a placebo, and some will also be sedated with propofol to block the psychedelic experience. Researchers will track mood changes over time to separate the effects of the drug from the experience.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DMT (N,N-Dimethyltryptamine)
What this could lead to: If it works, this could help develop depression treatments that don't require a full psychedelic experience.
What could go wrong: This is an early-phase study with only 112 participants, so results may not apply broadly. The use of propofol sedation adds complexity and risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER PSYCHEDELIC EXPERIENCES

Contacts and locations

Locations

University Hospital Basel
RECRUITING

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.